Is retatrutide legal to buy in France?

There is no legal route to buy it. It has no marketing authorisation, selling or distributing an unauthorised medicine is a criminal offence with up to five years' imprisonment, rising to seven when committed through a website, and personal import by post cannot be authorised for an unauthorised drug. Mere possession by a private individual is not itself penalised.

What has France done about online peptide sellers?

The ANSM ran an enforcement programme from September 2025: around ten platforms targeted, referrals to prosecutors, product withdrawal orders in October 2025, measures against seven websites in November 2025, and further withdrawal decisions in July 2026.

GLP1 Europe › Legality › France

Is retatrutide legal in France?

Q: What did the ANSM say about retatrutide?

In a warning published 2 July 2026 about peptides sold online, the ANSM named retatrutide, documented serious adverse effects including hospitalisations particularly involving it, and told the public never to use products labelled for research use only.

Last checked 14 August 2026 · About 7 minutes to read · Sources listed at the end

Short answer

Selling or advertising it can carry up to seven years in prison when done through a website. Importing it by post has no legal route. Possession itself is not penalised.

France is also the one country whose medicines agency has warned about retatrutide by name, and its instruction was blunt: never use a product marked "for research use only".

Read this first

This page describes published law and documented enforcement, on the date shown above. It is not legal advice, it can lag changes, and how the law applies to a specific person is a question for a lawyer in this country. Retatrutide itself has no marketing authorisation anywhere in the world, so everything here concerns an unauthorised medicine.

What the law says

The public health code requires a marketing authorisation before an industrially produced medicine reaches the market. Selling, distributing or brokering a medicine without one is a criminal offence carrying five years and a 375,000 euro fine, rising to seven years and 750,000 euros when the offence endangers health, is organised, or is committed through a communication network open to the public, which is to say a website. Advertising an unauthorised medicine carries the same penalties, and attempts are punishable.

Importing requires prior authorisation from the ANSM, France's medicines agency. A medicine with no authorisation anywhere cannot obtain the personal import authorisation the code describes, which closes the postal route entirely.

Possession, and the buyer's actual exposure

The code's criminal provisions target commercialisation, distribution, import and advertising. No provision penalises a private individual's mere possession of a non-controlled unauthorised medicine. A buyer's practical exposure is the parcel: seizure by customs, and the loss of whatever was paid.

Importing for personal use

Travellers may carry medicines for personal use up to three months of treatment without authorisation. Beyond personal quantities, customs describes the import as absolutely prohibited. By post, an authorised medicine can in some cases be sent under conditions; an unauthorised one cannot meet them. For retatrutide there is no compliant route into France by mail.

What enforcement actually looks like

France's enforcement against this market in 2025 and 2026 has been the most visible in Europe, and all of it aimed at sellers. In September 2025 the ANSM announced an action programme against illegal GLP-1 sales, targeting around ten platforms and referring cases to prosecutors. Sanitary police decisions followed: an October 2025 withdrawal order against one company's products presented as GLP-1 agonists, measures against seven websites run by two companies in November 2025, and further withdrawal decisions in July 2026. We found no documented prosecution of an individual buyer.

In July 2026 the agency published a warning about peptides sold online, naming retatrutide among others, documenting serious adverse effects including hospitalisations, particularly with retatrutide, and telling the public in terms: do not use products bearing the "research use only" label.

Does a "research use only" label change anything?

No. French law defines a medicine by what a product is presented as and what it does, the same two-limb test as EU law, so the label neither changes classification nor impressed the ANSM, whose warning treats RUO-labelled peptides as exactly what they are. The full legal background is here.

Common questions

Has anyone in France been prosecuted for buying?: We found no documented case. Documented enforcement is against websites and companies, with penalties designed for sellers. A seized parcel and lost money is the recorded buyer outcome.
Why does the website penalty matter?: Because the seven-year aggravated tier applies to offences committed through online sale to the public, it is the provision aimed squarely at the peptide-shop model, and the ANSM's referrals to prosecutors sit on top of it.
Is retatrutide specifically named anywhere in French enforcement?: Yes. The ANSM's July 2026 peptide warning names retatrutide and notes hospitalisations associated with it. France is so far the only European agency to have done this by name.

Sources

Code de la santé publique, articles L5111-1, L5121-8, L5421-2, L5124-13, R5121-108 and R5121-110, consolidated texts, checked 14 August 2026.
ANSM, "Peptides vendus en ligne : ne les utilisez pas", 2 July 2026, updated 22 July 2026, naming retatrutide.
ANSM, action programme against illegal GLP-1 sale and advertising, 11 September 2025; sanitary police decisions of 29 October 2025, 19 November 2025, 9 and 16 July 2026.
French customs, guidance on transporting and importing medicines as a private individual.

Not legal advice. Laws and enforcement practice change, and individual circumstances differ. For a decision that affects you, consult a lawyer qualified in France.